US Customs and Border Protection has postponed new customs filing and bond requirements for international mail shipments valued under USD 800 until 20 January 2027, giving businesses more time to prepare and delaying potential disruptions to personal prescription drug imports.
The US Customs and Border Protection agency announced on 14 October 2026 that it would postpone new requirements for international mail shipments. The compliance date shifted from 22 October 2026 to 20 January 2027, giving importers, brokers, and logistics companies 90 additional days to adjust their systems.
The rule targets shipments valued under USD 800, which have previously qualified for de minimis tariff exemptions. The change implements provisions from President Donald Trump’s spending and tax legislation, with the full package of modifications originally scheduled for July 2027.
As previously reported, on 13 August 2025, the US Court of International Trade upheld the Trump administration’s decision to end the de minimis tariff exemption for imports valued below USD 800.
How the rule works and who it affects
The new process requires electronic filing for postal shipments subject to Section 201, 232, or 301 tariffs. Shipments under FDA jurisdiction must also comply. All affected mail now requires a customs bond before entry.
The timing spared the agency from potential political backlash just 12 days before the 3 November election, when household affordability remains a central campaign issue.
Prescription drug imports face new obstacles
Americans routinely order medications from Canada and other countries where prices run substantially lower than domestic costs. The FDA officially prohibits individuals from importing foreign prescription drugs, though it retains discretion in limited cases.
The Canadian International Pharmacy Association warned that most routine personal orders from licensed pharmacies would face disruption under the original October deadline.
Congress members raised concerns about the rule. Seventy-one lawmakers signed a letter led by Democratic Representatives Jan Schakowsky of Illinois and Mark Pocan of Wisconsin, urging agencies to delay procedures unless personal-use drugs received protection.
Merith Basey, chief executive of Patients For Affordable Drugs, called the delay temporary relief rather than a lasting solution. Basey stated that halting personal importation practices creates gaps for patients already struggling with medication costs.
The CBP said the extended timeline prevents disruptions and closes gaps that smugglers have exploited, though the agency did not address medicines specifically in its announcement.
